Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Non-Current Assets (2017 - 2025)

Crinetics Pharmaceuticals (CRNX) has 9 years of Non-Current Assets data on record, last reported at $72.3 million in Q2 2025.

  • For Q2 2025, Non-Current Assets rose 19.01% year-over-year to $72.3 million; the TTM value through Jun 2025 reached $261.6 million, up 5.19%, while the annual FY2024 figure was $59.2 million, 3.26% down from the prior year.
  • Non-Current Assets reached $72.3 million in Q2 2025 per CRNX's latest filing, up from $70.3 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $72.3 million in Q2 2025 and bottomed at $5.0 million in Q1 2022.
  • Average Non-Current Assets over 5 years is $31.9 million, with a median of $8.5 million recorded in 2023.
  • Peak YoY movement for Non-Current Assets: fell 14.44% in 2021, then soared 903.16% in 2023.
  • A 5-year view of Non-Current Assets shows it stood at $6.3 million in 2021, then grew by 11.07% to $7.0 million in 2022, then surged by 775.29% to $61.2 million in 2023, then fell by 3.26% to $59.2 million in 2024, then grew by 22.14% to $72.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were $72.3 million in Q2 2025, $70.3 million in Q1 2025, and $59.2 million in Q4 2024.